NASDAQ:INDP Indaptus Therapeutics Q3 2025 Earnings Results & Report $3.17 +0.02 (+0.63%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$3.20 +0.03 (+0.95%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Indaptus Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$2.98 versus the -$4.17 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Indaptus Therapeutics EPS ResultsActual EPS-$2.98Consensus EPS -$4.17Beat/MissBeat by +$1.19One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersIndaptus Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsIndaptus Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Indaptus Therapeutics Q3 2025 Earnings FAQ Did Indaptus Therapeutics beat earnings estimates for Q3 2025? Indaptus Therapeutics (NASDAQ:INDP) reported earnings of -$2.98 per share for Q3 2025, beating the consensus estimate of -$4.17. The report was announced on Wednesday, November 12, 2025. When is Indaptus Therapeutics' next earnings date? Indaptus Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Indaptus Therapeutics on the company's earnings history page. Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics Reports Third Quarter 2026 Financial Results and Corporate UpdateNovember 13 at 4:31 PM | quiverquant.comQIndaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 13 at 4:05 PM | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 15 at 1:00 AM | Behind the Markets (Ad)Indaptus Therapeutics (NASDAQ:INDP) Stock Jumps 5.1% - Here's WhyNovember 7, 2026 | americanbankingnews.comIndaptus Therapeutics Extends Timeline for Private Placement FinancingSeptember 30, 2026 | tipranks.comIndaptus Therapeutics Shares Rise After Entering $24 Million Private PlacementSeptember 10, 2026 | finance.yahoo.comSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways. The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease. Indaptus is focused on developing its pipeline rather than marketing approved products. The company is headquartered in the United States, and its publicly described clinical work has included U.S. research sites.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
